Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

  • 1Email author,
  • 2,
  • 3,
  • 4,
  • 4 and
  • 4
BMC Medicine201311:193

https://doi.org/10.1186/1741-7015-11-193

  • Received: 20 August 2013
  • Accepted: 20 August 2013
  • Published:

The original article was published in BMC Medicine 2013 11:43

Correction

The authors [1] note that the standard errors in Table 3 (Table 1 here) are actually standard deviations. The reference to standard errors in the footnote has now been edited accordingly.

This is a Correction article on http://0-www.biomedcentral.com.brum.beds.ac.uk/1741-7015/11/43.
Table 1

Summary of laboratory parameters

 

PBO + MET (n = 137)

DAPA 2.5 mg + MET (n = 137)

DAPA 5 mg + MET (n = 137)

DAPA 10 mg + MET (n = 135)

Sodium (mmol/L)

    

n

72

77

87

93

Baseline

138.9 (2.3)

138.5 (2.9)

138.6 (2.3)

139.1 (2.2)

Change at week 102

-0.04 (2.7)

0.2 (2.8)

0.1 (2.6)

0.1 (2.6)

P vs PBO + MET

 

0.1434

0.1905

0.3978

Potassium (mmol/L)

    

n

72

77

87

93

Baseline

4.35 (0.47)

4.34 (0.46)

4.37 (0.39)

4.37 (0.43)

Change at week 102

-0.08 (0.55)

-0.01 (0.45)

-0.05 (0.35)

-0.07 (0.47)

P vs PBO + MET

 

0.3366

0.4563

0.9918

Serum creatinine (μmol/L)

    

n

72

77

88

93

Baseline

76.9 (17.9)

78.7 (18.1)

79.6 (19.3)

77.8 (17.8)

Change at week 102

-0.9 (10.3)

-1.8 (9.7)

-3.5 (12.7)

-2.7 (10.6)

P vs PBO + MET

 

0.9954

0.4720

0.9032

Serum uric acid (μmol/L) a

    

n

28

35

47

57

Baseline

314 (79)

322 (80)

323 (88)

323 (80)

Change at week 102

-1.78 (54.13)

-55.9 (50.32)

-46.4 (64.36)

-52.9 (64.36)

P vs PBO + MET

 

0.0054

0.0013

0.0002

Blood urea nitrogen (mmol/L)

    

n

72

77

88

93

Baseline

5.33 (1.55)

5.51 (1.41)

5.65 (1.81)

5.34 (1.41)

Change at week 102

0.56 (1.24)

0.70 (1.54)

0.42 (1.87)

0.73 (1.44)

P vs PBO + MET

 

0.2299

0.4169

0.0845

Haematocrit (%)

    

n

71

78

87

93

Baseline

42.61 (3.90)

42.38 (3.99)

42.15 (3.59)

42.88 (3.95)

Change at week 102

-1.43 (3.29)

0.84 (2.53)

1.35 (2.48)

1.54 (2.78)

P vs PBO + MET

 

<0.0001

<0.0001

<0.0001

Haemoglobin (g/L)

    

n

71

78

87

94

Baseline

142.8 (13.45)

142.5 (14.25)

141.6 (12.19)

143.6 (13.10)

Change at week 102

-4.9 (10.14)

1.5 (7.73)

3.1 (8.40)

4.1 (8.84)

P vs PBO + MET

 

<0.0001

<0.0001

<0.0001

Systolic blood pressure (mm Hg)

    

n

72

78

88

94

Baseline

128 (15)

127 (14)

127 (14)

126 (16)

Change at week 102

1.5 (13.7)

0.7 (16.1)

-1.1 (13.2)

-0.3 (15.0)

P vs PBO + MET

 

0.1111

0.0136

0.0067

Diastolic blood pressure (mm Hg)

    

n

72

78

88

94

Baseline

81 (9)

80 (9)

81 (9)

79 (10)

Change at Week 102

-1.0 (7.9)

-0.1 (8.1)

-1.5 (8.1)

-1.2 (10.1)

P vs PBO + MET

 

0.6605

0.2140

0.1075

Data are means (SD) at baseline or mean changes (SD) from baseline at week 102 including data after rescue unless noted. n is the number of treated patients with non-missing baseline and Week 102 values for the specific test. a Excluding data after rescue. Abbreviations: SD standard deviation, SE standard error, PBO placebo, MET metformin, DAPA dapagliflozin.

Notes

Authors’ Affiliations

(1)
Life and Health Sciences, Aston University, Birmingham, B4 7ET, UK
(2)
Endocrine Division, Universidade Federal do Rio Grande do Sul, Avenida Paulo Gama 110-Reitoria, Porto Alegre, 90040-060, Brazil
(3)
Global Biometric Services, Bristol-Myers Squibb, Parc de l’Alliance, Avenue de Finlande 4, Braine I’Alleud, B-1420, Belgium
(4)
Global Clinical Research, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ 08543, USA

References

  1. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Medicine. 2013, 11: 43-10.1186/1741-7015-11-43.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1741-7015/11/193/prepub

Copyright

© Bailey et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement